CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft Tissue Repair Matrix to treat tendinopathy, which is exclusively distributed by Arthrex in Europe, the Middle East, India and Africa.
CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft...
CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft Tissue Repair Matrix to treat tendinopathy, which is exclusively distributed by Arthrex in Europe, the Middle East, India and Africa.
Copy to clipboard 
